On Dec. 29, 1993, the U.S. Food and Drug Administration (FDA) approved indications for oral risperidone (tablets, oral solution, and M-TABs) include the treatment of schizophrenia (in adults and children aged 13 and older), bipolar I acute manic or mixed episodes as monotherapy (in adults and children aged 10 and older), bipolar I acute manic or mixed episodes adjunctive with lithium or valproate (in adults), and autism-associated irritability (in children aged 5 and older).

This medication may be administered in oral form (tablets, solution, or dissolvable) or as a long-acting injection. Patients should not cut or chew the orally disintegrating tablet formulation. It is also available in injectable form.